公众号 / 文章呼吸衰竭与机械通气重症综合管理与镇静镇痛消化、代谢与肾脏急症

流感病毒相关危重症:预防、诊断与治疗

Influenza virus-related critical illness: prevention, diagnosis, treatment.
PubMed 文献 · Crit Care · 2019-06-12
一句话结论对危重流感患者应尽早经肠道给予标准剂量奥司他韦(成人75 mg 每日两次),不推荐常规使用辅助糖皮质激素。

本文综述了流感病毒相关危重症的预防、诊断与治疗。年度流感疫苗接种推荐用于美国所有6月龄及以上人群,观察性研究显示接种可降低住院、ICU入住和死亡风险。危重患者应考虑流感诊断,推荐对住院患者呼吸道标本进行分子检测,不推荐抗原检测。危重下呼吸道疾病患者应检测气管吸引物(优先)或支气管肺泡灌洗液。观察性研究显示神经氨酸酶抑制剂抗病毒治疗与生存获益相关,推荐尽早经肠道给予标准剂量奥司他韦(成人75 mg 每日两次)。基于观察性数据提示 harms,不推荐对住院流感儿童或成人(包括危重患者)常规使用辅助糖皮质激素,除非有其他临床指征。

要点

  • 危重流感患者应尽早经肠道给予标准剂量奥司他韦(成人75 mg 每日两次),早期启动抗病毒治疗临床获益最大。
  • 住院患者流感检测推荐分子检测,不推荐抗原检测;抗原阴性结果不应作为临床决策依据。
  • 危重下呼吸道疾病患者应检测气管吸引物(优先)或支气管肺泡灌洗液标本的流感病毒分子检测。
  • 不推荐对住院流感儿童或成人(包括危重患者)常规使用辅助糖皮质激素,除非有其他临床指征如哮喘或COPD急性加重、脓毒性休克。
  • 年度流感疫苗接种推荐用于美国所有6月龄及以上人群,观察性研究显示可降低住院、ICU入住和死亡风险。

适用人群与场景

  • 美国及全球范围内年度季节性流感流行中的危重患者。
  • 因基础慢性合并症加重、社区获得性肺炎和呼吸衰竭等并发症入院的危重患者应考虑流感诊断。
  • 美国所有6月龄及以上人群推荐年度流感疫苗接种;世界其他地区流感相关并发症风险增加人群(如幼儿、老年人)也推荐接种。

处置流程与药物剂量

  • 推荐对住院患者呼吸道标本进行流感分子检测;不推荐危重患者使用抗原检测,因其敏感性较低,抗原阴性结果不应作为临床决策依据。
  • 危重下呼吸道疾病患者应检测气管吸引物(优先)或支气管肺泡灌洗液标本(若因其他诊断目的已采集)的流感病毒分子检测。
  • 推荐尽早经肠道给予标准剂量奥司他韦(成人75 mg 每日两次),因其在危重患者中吸收良好,且早期启动抗病毒治疗临床获益最大。
  • 不推荐对住院流感儿童或成人(包括危重患者)常规使用辅助糖皮质激素,除非有其他临床指征如哮喘或COPD急性加重、脓毒性休克。

研究设计与关键结果

  • 观察性研究报道流感疫苗接种可降低需住院的严重疾病、ICU入住和死亡风险。
  • 观察性研究报道危重成人流感患者接受神经氨酸酶抑制剂抗病毒治疗与生存获益相关。
  • 基于观察性数据提示 harms,辅助糖皮质激素治疗目前不推荐用于住院流感儿童或成人(包括危重患者),除非有其他临床指征。

证据类型、等级与局限

  • 综述;证据来自观察性研究。
  • 局限:原文未报告局限性

对床旁实践的改变

  • 危重流感患者应尽早经肠道给予标准剂量奥司他韦(成人75 mg 每日两次),不应等待检测结果。
  • 不应使用抗原检测阴性结果排除流感;住院患者应使用分子检测,危重下呼吸道疾病患者应检测气管吸引物或支气管肺泡灌洗液。
  • 不应常规对住院流感患者(包括危重患者)使用辅助糖皮质激素,除非有哮喘或COPD急性加重、脓毒性休克等其他临床指征。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Annual seasonal influenza epidemics of variable severity result in significant morbidity and mortality in the United States (U.S.) and worldwide. In temperate climate countries, including the U.S., influenza activity peaks during the winter months. Annual influenza vaccination is recommended for all persons in the U.S. aged 6 months and older, and among those at increased risk for influenza-related complications in other parts of the world (e.g. young children, elderly). Observational studies have reported effectiveness of influenza vaccination to reduce the risks of severe disease requiring hospitalization, intensive care unit admission, and death. A diagnosis of influenza should be considered in critically ill patients admitted with complications such as exacerbation of underlying chronic comorbidities, community-acquired pneumonia, and respiratory failure during influenza season. Molecular tests are recommended for influenza testing of respiratory specimens in hospitalized patients. Antigen detection assays are not recommended in critically ill patients because of lower sensitivity; negative results of these tests should not be used to make clinical decisions, and respiratory specimens should be tested for influenza by molecular assays. Because critically ill patients with lower respiratory tract disease may have cleared influenza virus in the upper respiratory tract, but have prolonged influenza viral replication in the lower respiratory tract, an endotracheal aspirate (preferentially) or bronchoalveolar lavage fluid specimen (if collected for other diagnostic purposes) should be tested by molecular assay for detection of influenza viruses.Observational studies have reported that antiviral treatment of critically ill adult influenza patients with a neuraminidase inhibitor is associated with survival benefit. Since earlier initiation of antiviral treatment is associated with the greatest clinical benefit, standard-dose oseltamivir (75 mg twice daily in adults) for enteric administration is recommended as soon as possible as it is well absorbed in critically ill patients. Based upon observational data that suggest harms, adjunctive corticosteroid treatment is currently not recommended for children or adults hospitalized with influenza, including critically ill patients, unless clinically indicated for another reason, such as treatment of asthma or COPD exacerbation, or septic shock. A number of pharmaceutical agents are in development for treatment of severe influenza.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Chow EJ, Doyle JD, Uyeki TM, et al. Influenza virus-related critical illness: prevention, diagnosis, treatment. Crit Care. 2019. PMID: 31189475. doi:10.1186/s13054-019-2491-9

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。